Skip to main content

Advertisement

Table 1 Overview of longitudinal cohort data from Papua New Guinea and Thailand

From: Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses

  Papua New Guinea (n = 504) Thailand (n = 999)
Placebo arm (n = 257) Primaquine arm (n = 247)
Gender (male) 49.8% (128) 48.6% (120) 46.2% (462)
Age (years) 7.5 (4.9, 10.4) 7.6 (4.8, 10.4) 23 (1, 82)
Bednet usage 93.4% (240) 93.1% (230) 88.8% (888)
Duration of follow-up (days) 224 (56, 231) 224 (42, 229) 369 (360, 378)
Proportion of data missing 12.3% 10.1% 8.3%
Any P. vivax infection by qPCR 69.6% (179) 27.9% (69) 11.9% (119)
Any P. vivax infection by LM 54.5% (140) 21.9% (54)
Number of P. vivax genotypes 2.2 (0, 12) 0.7 (0, 7) 0.3 (0, 11)
Any P. falciparum infection by qPCR 37.0% (95) 34.0% (84) 2.4% (24)
Any P. falciparum infection by LM 23.7% (61) 27.9% (69)
Number of P. falciparum genotypes 0.6 (0, 9) 0.5 (0, 6) 0.03 (0, 6)
Any fever 53.7% (138) 62.3% (154) 24.7% (247)
Any fever with qPCR+ P. vivax 10.1% (26) 4.0% (10) 2.1% (21)
Any fever with qPCR+ P. falciparum 9.7% (25) 16.6% (41) 0.3% (3)
  1. The data from PNG is for the period after the initial drug regimen. Missing data is defined as the proportion of samples scheduled in the study protocols missed. Data on age, numbers of genotypes detected during follow-up, and duration of follow-up are presented as mean and ranges. Light microscopy (LM) data was not available for the Thai samples